Company & Sponsor Intelligence
UCB Biopharma SRL
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials3
Recruiting0
Completed2
Countries2
Therapeutic footprint
epilepsyparkinsons
Indexed studies
NCT04666610A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
epilepsy · United StatesPHASE3
epilepsy · United StatesPHASE3
NCT04651153A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)
parkinsons · NetherlandsPHASE1
parkinsons · NetherlandsPHASE1
NCT04519645A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
epilepsy · United StatesPHASE2
epilepsy · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →